First-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters

Share this article
Share this article
FRANKLIN LAKES, N.J., Feb. 2, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs).
The results of the CLEAN3 trial
The Lancet Infectious Diseases, showed the use of the BD vascular care solution resulted in fewer PIVC failures compared with the standard group (34.8% vs. 47.5%, respectively) and extended the median time between catheter insertion and failure (50.4 hours vs 30.0 hours, respectively). PIVC failure was defined as any premature removal of PIVC before end of treatment – other than for routine replacement – and included phlebitis, infiltration, occlusion, dislodgment, local infection and catheter-related bloodstream infection (whichever occurred first).

Related Keywords

Poitiers ,Poitou Charentes ,France ,Netherlands ,Guenezan ,Bretagne ,Drugeon ,Franche Comter ,Insyte Autoguard ,Klaus Hoerauf ,Troy Kirkpatrick ,Kristenm Stewart ,Medication Delivery Solutions ,Poitiers University Hospital ,Appl Health Econ ,Lancet Infectious Diseases ,Becton Dickinson ,Infect Dis ,Infus Nurs ,Health Econ Policy ,பிரான்ஸ் ,நெதர்லாந்து ,ப்ரெடக்ந்ய் ,கிளாஸ் ொேறோஉப் ,டிராய் கர்க்‌ப்யாட்ரிக் ,மருந்து டெலிவரி தீர்வுகள் ,அப்பில் ஆரோக்கியம் ஏகொன் ,பெக்டன் டிக்கின்சன் ,தொற்று திஸ் ,ஆரோக்கியம் ஏகொன் பாலிஸீ ,